174 related articles for article (PubMed ID: 20945149)
21. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.
Green J; Czanner G; Reeves G; Watson J; Wise L; Beral V
BMJ; 2010 Sep; 341():c4444. PubMed ID: 20813820
[TBL] [Abstract][Full Text] [Related]
22. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.
Vestergaard P; Schwartz F; Rejnmark L; Mosekilde L
Osteoporos Int; 2011 Mar; 22(3):993-1001. PubMed ID: 21165600
[TBL] [Abstract][Full Text] [Related]
23. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
24. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.
Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
Osteoporos Int; 2010 Sep; 21(9):1591-7. PubMed ID: 19859641
[TBL] [Abstract][Full Text] [Related]
25. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database.
Abrahamsen B
Osteoporos Int; 2013 Jan; 24(1):369-72. PubMed ID: 22572963
[TBL] [Abstract][Full Text] [Related]
26. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates.
Sharma A; Einstein AJ; Vallakati A; Arbab-Zadeh A; Walker MD; Mukherjee D; Homel P; Borer JS; Lichstein E
Am J Cardiol; 2014 Jun; 113(11):1815-21. PubMed ID: 24837258
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates and risk of atrial fibrillation: a meta-analysis.
Kim SY; Kim MJ; Cadarette SM; Solomon DH
Arthritis Res Ther; 2010; 12(1):R30. PubMed ID: 20170505
[TBL] [Abstract][Full Text] [Related]
29. Heart failure in patients treated with bisphosphonates.
Grove EL; Abrahamsen B; Vestergaard P
J Intern Med; 2013 Oct; 274(4):342-50. PubMed ID: 23679231
[TBL] [Abstract][Full Text] [Related]
30. A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.
Kwon JW; Park EJ; Jung SY; Sohn HS; Ryu H; Suh HS
J Dent Res; 2015 Sep; 94(9 Suppl):212S-9S. PubMed ID: 26001708
[TBL] [Abstract][Full Text] [Related]
31. Incident acute pseudogout and prior bisphosphonate use: Matched case-control study in the UK-Clinical Practice Research Datalink.
Roddy E; Muller S; Paskins Z; Hider SL; Blagojevic-Bucknall M; Mallen CD
Medicine (Baltimore); 2017 Mar; 96(12):e6177. PubMed ID: 28328803
[TBL] [Abstract][Full Text] [Related]
32. Statin Use and Risk of Atrial Fibrillation or Flutter: A Population-based Case-Control Study.
Veronese G; Montomoli J; Schmidt M; Horváth-Puhó E; Sørensen HT
Am J Ther; 2015; 22(3):186-94. PubMed ID: 23567792
[TBL] [Abstract][Full Text] [Related]
33. Oral bisphosphonates do not increase the risk of severe upper gastrointestinal complications: a nested case-control study.
Ghirardi A; Scotti L; Vedova GD; D'Oro LC; Lapi F; Cipriani F; Caputi AP; Vaccheri A; Gregori D; Gesuita R; Vestri A; Staniscia T; Mazzaglia G; Corrao G;
BMC Gastroenterol; 2014 Jan; 14():5. PubMed ID: 24397769
[TBL] [Abstract][Full Text] [Related]
34. Oral bisphosphonates and atrial fibrillation.
Majumdar SR
BMJ; 2008 Apr; 336(7648):784-5. PubMed ID: 18334526
[TBL] [Abstract][Full Text] [Related]
35. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
John Camm A
Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.
Oh YH; Yoon C; Park SM
World J Gastroenterol; 2012 Oct; 18(40):5779-88. PubMed ID: 23155320
[TBL] [Abstract][Full Text] [Related]
37. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.
Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW
PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968
[TBL] [Abstract][Full Text] [Related]
38. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Lu PY; Hsieh CF; Tsai YW; Huang WF
Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
[TBL] [Abstract][Full Text] [Related]
39. Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study.
Viggers R; Al-Mashhadi Z; Starup-Linde J; Vestergaard P
Front Endocrinol (Lausanne); 2021; 12():771426. PubMed ID: 34867816
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.
Etminan M; Forooghian F; Maberley D
CMAJ; 2012 May; 184(8):E431-4. PubMed ID: 22470169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
